{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:52:35Z","timestamp":1790999555118,"version":"4.1.0"},"reference-count":52,"publisher":"Institute of Physiology of the Czech Academy of Sciences","issue":"3\/2025","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Butyrylcholinesterase (BChE) has recently been associated with metabolic imbalance. A correlation between plasma activity and lipid and glucose metabolism has been reported in animal models and human patients. Here, we investigated plasma BChE activity in a rat model of comorbid hypertension and type 1 diabetes mellitus (DM) induced by a single injection of streptozotocin (STZ, 55 mg\/kg) in male spontaneously hypertensive rats (SHR) (SHR+DM). The SHR+DM animals exhibit the main characteristics of the human comorbid pathology, including hypertension and hyperglycemia. Although STZ lowered blood pressure in SHR, the animals remained hypertensive as compared to the Wistar controls. Plasma levels of triacylglycerols, cholesterol and HDL were increased, while markers of liver damage such as ALT, AST, were increased and albumin was decreased. Plasma BChE activities were similar in Wistar and SHR. In SHR+DM, plasma BChE activity was increased by 43 %. Interestingly, liver BChE activity and relative mRNA expression were decreased by 60 % in SHR and SHR+DM. While plasma BChE activity is often used as a clinical marker of liver injury, our results suggest that it may not be a reliable indicator.<\/jats:p>","DOI":"10.33549\/physiolres.935558","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:54:23Z","timestamp":1753264463000},"page":"471-480","source":"Crossref","is-referenced-by-count":6,"title":["Altered Plasma Butyrylcholinesterase Activity in Streptozotocin-Induced Diabetic Hypertensive Rats Does Not Reflect Impaired Liver Function"],"prefix":"10.33549","author":[{"given":"T","family":"Hodbod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Szmicsekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cinakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Stefikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Krivosikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kralov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hrabovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.\tJbilo O, Bartels CF, Chatonnet A, Toutant JP, Lockridge O. Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 1994;32:1445-1457. https:\/\/doi.org\/10.1016\/0041-0101(94)90416-2","DOI":"10.1016\/0041-0101(94)90416-2"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.\tLockridge O, Norgren RB, Johnson RC, Blake TA. Naturally Occurring Genetic Variants of Human Acetylcholinesterase and Butyrylcholinesterase and Their Potential Impact on the Risk of Toxicity from Cholinesterase Inhibitors. Chem Res Toxicol 2016;29:1381-1392. https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00228","DOI":"10.1021\/acs.chemrestox.6b00228"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.\tLockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 2015;148:34-46. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.11.011","DOI":"10.1016\/j.pharmthera.2014.11.011"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.\tSridhar GR, Gumpeny L. Emerging significance of butyrylcholinesterase. World J Exp Med 2024;14:87202. https:\/\/doi.org\/10.5493\/wjem.v14.i1.87202","DOI":"10.5493\/wjem.v14.i1.87202"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.\tLi B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000;75:1320-1331. https:\/\/doi.org\/10.1046\/j.1471-4159.2000.751320.x","DOI":"10.1046\/j.1471-4159.2000.751320.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.\tManoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta Int J Clin Chem 2007;378:128-135. https:\/\/doi.org\/10.1016\/j.cca.2006.11.005","DOI":"10.1016\/j.cca.2006.11.005"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.\tLi B, Duysen EG, Lockridge O. The butyrylcholinesterase knockout mouse is obese on a high-fat diet. Chem Biol Interact 2008;175:88-91. https:\/\/doi.org\/10.1016\/j.cbi.2008.03.009","DOI":"10.1016\/j.cbi.2008.03.009"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.\tLockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 1990;47:35-60. https:\/\/doi.org\/10.1016\/0163-7258(90)90044-3","DOI":"10.1016\/0163-7258(90)90044-3"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.\tMesulam M-M, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627-639. https:\/\/doi.org\/10.1016\/S0306-4522(01)00613-3","DOI":"10.1016\/s0306-4522(01)00613-3"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.\tDuysen EG, Li B, Darvesh S, Lockridge O. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 2007;233:60-69. https:\/\/doi.org\/10.1016\/j.tox.2006.11.069","DOI":"10.1016\/j.tox.2006.11.069"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.\tSchopfer LM, Lockridge O, Brimijoin S. Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to desacyl ghrelin. Gen Comp Endocrinol 2015;224:61-68. https:\/\/doi.org\/10.1016\/j.ygcen.2015.05.017","DOI":"10.1016\/j.ygcen.2015.05.017"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.\tBrimijoin S, Chen VP, Pang Y-P, Geng L, Gao Y. Physiological roles for butyrylcholinesterase: A BChE-ghrelin axis. Chem Biol Interact 2016;259:271-275. https:\/\/doi.org\/10.1016\/j.cbi.2016.02.013","DOI":"10.1016\/j.cbi.2016.02.013"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tChen VP, Gao Y, Geng L, Brimijoin S. Butyrylcholinesterase regulates central ghrelin signaling and has an impact on food intake and glucose homeostasis. Int J Obes (Lond) 2017;41:1413-1419. https:\/\/doi.org\/10.1038\/ijo.2017.123","DOI":"10.1038\/ijo.2017.123"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.\tRandell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005;38:799-805. https:\/\/doi.org\/10.1016\/j.clinbiochem.2005.04.008","DOI":"10.1016\/j.clinbiochem.2005.04.008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.\tIwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007;46:1633-1639. https:\/\/doi.org\/10.2169\/internalmedicine.46.0049","DOI":"10.2169\/internalmedicine.46.0049"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.\tMolina-Pintor IB, Rojas-Garc\u00eda AE, Bernal-Hern\u00e1ndez YY, Medina-D\u00edaz IM, Gonz\u00e1lez-Arias CA, Barr\u00f3n-Vivanco BS. Relationship between butyrylcholinesterase activity and lipid parameters in workers occupationally exposed to pesticides. Environ Sci Pollut Res Int 2020;27:39365-39374. https:\/\/doi.org\/10.1007\/s11356-020-08197-2","DOI":"10.1007\/s11356-020-08197-2"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.\tVallianou NG, Evangelopoulos AA, Bountziouka V, Bonou MS, Katsagoni C, Vogiatzakis ED, Avgerinos PC, et al. Association of butyrylcholinesterase with cardiometabolic risk factors among apparently healthy adults. J Cardiovasc Med (Hagerstown) 2014;15:377-383. https:\/\/doi.org\/10.2459\/JCM.0b013e3283627700","DOI":"10.2459\/jcm.0b013e3283627700"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.\tAlc\u00e2ntara VM, Chautard-Freire-Maia EA, Scartezini M, Cerci MSJ, Braun-Prado K, Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 2002;62:399-404. https:\/\/doi.org\/10.1080\/00365510260296564","DOI":"10.1080\/00365510260296564"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.\tTangvarasittichai S, Pongthaisong S, Meemark S, Tangvarasittichai O. Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels. Indian J Clin Biochem IJCB 2015;30:275-280. https:\/\/doi.org\/10.1007\/s12291-014-0443-3","DOI":"10.1007\/s12291-014-0443-3"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.\tKutty KM, Payne RH. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994;8:247-250. https:\/\/doi.org\/10.1002\/jcla.1860080411","DOI":"10.1002\/jcla.1860080411"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.\tAnnapurna V, Senciall I, Davis AJ, Kutty KM. Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia 1991;34:320-324. https:\/\/doi.org\/10.1007\/BF00405003","DOI":"10.1007\/bf00405003"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.\tKumar V, Agarwal S, Saboo B, Makkar B. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Int J Diabetes Dev Ctries 2022;42:576-605. https:\/\/doi.org\/10.1007\/s13410-022-01143-7","DOI":"10.1007\/s13410-022-01143-7"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.\tPassarella P, Kiseleva TA, Valeeva FV, Gosmanov AR. Hypertension Management in Diabetes: 2018 Update. Diabetes Spectr Publ Am Diabetes Assoc 2018;31:218-224. https:\/\/doi.org\/10.2337\/ds17-0085","DOI":"10.2337\/ds17-0085"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.\tIto M, Kondo Y, Nakatani A, Naruse A. New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin. Biol Pharm Bull 1999;22:988-989. https:\/\/doi.org\/10.1248\/bpb.22.988","DOI":"10.1248\/bpb.22.988"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.\tSzkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001;50:537-546. https:\/\/doi.org\/10.33549\/physiolres.930111","DOI":"10.33549\/physiolres.930111"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.\tCalder PC, Geddes R. Post mortem glycogenolysis is a combination of phosphorolysis and hydrolysis. Int J Biochem 1990;22:847-856. https:\/\/doi.org\/10.1016\/0020-711X(90)90288-E","DOI":"10.1016\/0020-711x(90)90288-e"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.\tDingova D, Leroy J, Check A, Garaj V, Krejci E, Hrabovska A. Optimal detection of cholinesterase activity in biological samples: modifications to the standard Ellman's assay. Anal Biochem 2014;462:67-75. https:\/\/doi.org\/10.1016\/j.ab.2014.05.031","DOI":"10.1016\/j.ab.2014.05.031"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.\tCollado-Mesa F, Colhoun HM, Stevens LK, Boavida J, Ferriss JB, Karamanos B, Kempler P, et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet Med J Br Diabet Assoc 1999;16:41-48. https:\/\/doi.org\/10.1046\/j.1464-5491.1999.00007.x","DOI":"10.1046\/j.1464-5491.1999.00007.x"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.\tTatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res 2017;40:795-806. https:\/\/doi.org\/10.1038\/hr.2017.67","DOI":"10.1038\/hr.2017.67"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.\tLiu W, Higashikuni Y, Sata M. Optimizing antihypertensive therapy in patients with diabetes mellitus. Hypertens Res 2023;46:797-800. https:\/\/doi.org\/10.1038\/s41440-022-01150-5","DOI":"10.1038\/s41440-022-01150-5"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.\tPassarella P, Kiseleva TA, Valeeva FV, Gosmanov AR. Hypertension Management in Diabetes: 2018 Update. Diabetes Spectr Publ Am Diabetes Assoc 2018;31:218-224. https:\/\/doi.org\/10.2337\/ds17-0085","DOI":"10.2337\/ds17-0085"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.\tGrossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol 2017;16:3. https:\/\/doi.org\/10.1186\/s12933-016-0485-3","DOI":"10.1186\/s12933-016-0485-3"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.\tNordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-635. https:\/\/doi.org\/10.1016\/S0140-6736(14)61177-6","DOI":"10.1016\/s0140-6736(14)61177-6"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tAustin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc 1997;56:667-670. https:\/\/doi.org\/10.1079\/PNS19970066","DOI":"10.1079\/PNS19970066"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.\tSomani P, Singh HP, Saini RK, Rabinovitch A. Streptozotocin-induced diabetes in the spontaneously hypertensive rat. Metabolism 1979;28:1075-1077. https:\/\/doi.org\/10.1016\/0026-0495(79)90144-6","DOI":"10.1016\/0026-0495(79)90144-6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.\tSusic D, Mandal AK, Jovovic DJ, Radujkovic G, Kentera D. Streptozotocin-induced diabetes mellitus lowers blood pressure in spontaneously hypertensive rat. Clin Exp Hypertens A 1990;12:1021-1035. https:\/\/doi.org\/10.3109\/10641969009073515","DOI":"10.3109\/10641969009073515"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.\tCalderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006;52:845-852. https:\/\/doi.org\/10.1373\/clinchem.2005.059857","DOI":"10.1373\/clinchem.2005.059857"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.\tHickman HD. Slowing blood flow to fight viral infection. Science 2019;363:585-586. https:\/\/doi.org\/10.1126\/science.aaw3618","DOI":"10.1126\/science.aaw3618"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.\tOlofsson PS, Steinberg BE, Sobbi R, Cox MA, Ahmed MN, Oswald M, Szekeres F, et al. Blood pressure regulation by CD4+ lymphocytes expressing choline acetyltransferase. Nat Biotechnol 2016;34:1066-1071. https:\/\/doi.org\/10.1038\/nbt.3663","DOI":"10.1038\/nbt.3663"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.\tCox MA, Duncan GS, Lin GHY, Steinberg BE, Yu LX, Brenner D, Buckler LN, et al. Choline acetyltransferase-expressing T cells are required to control chronic viral infection. Science 2019;363:639-644. https:\/\/doi.org\/10.1126\/science.aau9072","DOI":"10.1126\/science.aau9072"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.\tTarnawski L, Shavva VS, Kort EJ, Zhuge Z, Nilsson I, Gallina AL, Mart\u00ednez-Enguita D, et al. Cholinergic regulation of vascular endothelial function by human ChAT+ T cells. Proc Natl Acad Sci U S A 2023;120:e2212476120. https:\/\/doi.org\/10.1073\/pnas.2212476120","DOI":"10.1101\/2021.04.27.441632"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.\tCardoso AM, Abdalla FH, Bagatini MD, Martins CC, da Fiorin FS, Baldissarelli J, Costa P, et al. Swimming training prevents alterations in acetylcholinesterase and butyrylcholinesterase activities in hypertensive rats. Am J Hypertens 2014;27:522-529. https:\/\/doi.org\/10.1093\/ajh\/hpt030","DOI":"10.1093\/ajh\/hpt030"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.\tSzmicsekov\u00e1 K, Bies Piv\u00e1\u010dkov\u00e1 L, Kili\u00e1nov\u00e1 Z, Slobodov\u00e1 \u013d, K\u0159enek P, Hrabovsk\u00e1 A. Aortic butyrylcholinesterase is reduced in spontaneously hypertensive rats. Physiol Res 2021;70:809-813. https:\/\/doi.org\/10.33549\/physiolres.934669","DOI":"10.33549\/physiolres.934669"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.\tTrippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 1981;48:309-319. https:\/\/doi.org\/10.1161\/01.RES.48.3.309","DOI":"10.1161\/01.res.48.3.309"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.\tK\u00fcng CF, Moreau P, Takase H, L\u00fcscher TF. L-NAME Hypertension Alters Endothelial and Smooth Muscle Function in Rat Aorta. Hypertension 1995;26:744-751. https:\/\/doi.org\/10.1161\/01.HYP.26.5.744","DOI":"10.1161\/01.hyp.26.5.744"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.\tVanhoutte PM. Endothelium-Dependent Contractions in Hypertension. Hypertension 2011;57:526-531. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.165100","DOI":"10.1161\/hypertensionaha.110.165100"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.\tWong MS-K, Vanhoutte PM. COX-mediated endothelium-dependent contractions: from the past to recent discoveries. Acta Pharmacol Sin 2010;31:1095-1102. https:\/\/doi.org\/10.1038\/aps.2010.127","DOI":"10.1038\/aps.2010.127"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.\tChen VP, Gao Y, Geng L, Stout MB, Jensen MD, Brimijoin S. Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet. Endocrinology 2016;157:3086-3095. https:\/\/doi.org\/10.1210\/en.2016-1166","DOI":"10.1210\/en.2016-1166"},{"key":"ref48","unstructured":"49.\tLuci\u0107 Vrdoljak A, Bradamante V, Radi\u0107 B, Peraica M, Fuchs R, Reiner Z. Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats. Acta Pharm 2005;55:177-185."},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.\tAbbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, Bhatnagar D, Boulton AJ, Durrington PN. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) 1993;85:77-81. https:\/\/doi.org\/10.1042\/cs0850077","DOI":"10.1042\/cs0850077"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.\tSantarpia L, Alfonsi L, Castiglione F, Pagano MC, Cioffi I, Rispo A, Sodo M, Contaldo F, Pasanisi F. Nutritional Rehabilitation in Patients with Malnutrition Due to Crohn's Disease. Nutrients 2019;11:2947. https:\/\/doi.org\/10.3390\/nu11122947","DOI":"10.3390\/nu11122947"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.\tSantarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle 2013;4:31-39. https:\/\/doi.org\/10.1007\/s13539-012-0083-5","DOI":"10.1007\/s13539-012-0083-5"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:54:25Z","timestamp":1753264465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_471.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":52,"journal-issue":{"issue":"3\/2025","published-online":{"date-parts":[[2025,7,21]]}},"URL":"https:\/\/doi.org\/10.33549\/physiolres.935558","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}